In breast tumors, we clearly identified that the subgroup ER+/HER2−/PR- showed overall higher kinase activity compared to the other PR+ subgroups in all three peptide clusters identified through unsupervised clustering in Fig. 1a. This evidence concerns the gene ESR1 and breast neoplasm.